Tony Nimeh, MD
Urology · Fairbanks, AKNPI 1760804777
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Neotract Inc. accounts for 65.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $2,918 and has fallen 94.8% since, to $151 in 2024.
Across 75 payments — averaging $58.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$3K
- Astellas Pharma US Inc$247
- Teleflex LLC$246
- Johnson & Johnson$148
- Boston Scientific$137
- Endo Pharmaceuticals Inc.$137
- plus $625 from 15 others
What the payments were for
- Travel & lodging$2,14449%
- Food & beverage$2,14949%
- Education$1263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 17 | $2,878 |
| Astellas Pharma US Inc | 9 | $247 |
| Teleflex LLC | 6 | $246 |
| Johnson & Johnson(2 entities) | 3 | $148 |
| Boston Scientific | 6 | $137 |
| Endo Pharmaceuticals Inc. | 8 | $137 |
| 180 Medical, Inc. | 5 | $132 |
| Dornier Medtech America, Inc | 1 | $102 |
| Coloplast | 2 | $64 |
| Dendreon Pharmaceuticals LLC | 2 | $46 |
| AbbVie | 2 | $41 |
| Laborie Medical Technologies Corp. | 1 | $39 |
| Olympus America Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $27 |
| Bayer | 1 | $26 |
| Ambu Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Travere Therapeutics, Inc. | 5 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,410
- Consumables & Accessories$102
How this compares
$4,419 in reported general payments places this provider in the 80th percentile of 28 urology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $15,540 |
| GemtesaVibegron | 11 | $14,792 |
| Tamsulosin Hcl | 240 | $4,731 |
| Solifenacin Succinate | 45 | $1,962 |
| Finasteride | 92 | $1,527 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $464 |
| Levofloxacin | 27 | $51 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $247 | $15,54015 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $14,79211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 urology providers in Alaska.
Other urology in Fairbanks
- David SharpFairbanks$6K
- Max LevittFairbanks$4K
- Shannon SmithFairbanks$3K
- Joshua LoganAnchorage$16K
- William ClarkAnchorage$9K
- Elysia SpencerAnchorage$8K
- Andre GodetAnchorage$5K
- Bryan WilsonAnchorage$4K
- Doug ChoJber$4K
- Mariam MillerAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.